A citation-based method for searching scientific literature

Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, Johan M Kros, Mathilde C M Kouwenhoven, Jean-Yves Delattre, Hans J J A Bernsen, Marc Frenay, Cees C Tijssen, Wolfgang Grisold, László Sipos, Roelien H Enting, Pim J French, Winand N M Dinjens, Charles J Vecht, Anouk Allgeier, Denis Lacombe, Thierry Gorlia, Khê Hoang-Xuan. J Clin Oncol 2013
Times Cited: 714



David N Louis, Arie Perry, Pieter Wesseling, Daniel J Brat, Ian A Cree, Dominique Figarella-Branger, Cynthia Hawkins, H K Ng, Stefan M Pfister, Guido Reifenberger, Riccardo Soffietti, Andreas von Deimling, David W Ellison. Neuro Oncol 2021
Times Cited: 929




List of shared articles



Times cited

Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma.
Evanthia Galanis, Patrick Y Wen, John F de Groot, Michael Weller. Hematol Oncol Clin North Am 2022
1

Back to the Future: Charting the Direction of Lower Grade Glioma Trials With Lessons From the Present and Past.
Michelle M Kim, Jona A Hattangadi-Gluth, Kristin J Redmond, Daniel M Trifiletti, Scott G Soltys, Michael T Milano. Int J Radiat Oncol Biol Phys 2022
0

Oligosarcomas, IDH-mutant are distinct and aggressive.
Abigail K Suwala, Marius Felix, Dennis Friedel, Damian Stichel, Daniel Schrimpf, Felix Hinz, Ekkehard Hewer, Leonille Schweizer, Hildegard Dohmen, Ute Pohl,[...]. Acta Neuropathol 2022
3

MR Fingerprinting-A Radiogenomic Marker for Diffuse Gliomas.
Elisabeth Springer, Pedro Lima Cardoso, Bernhard Strasser, Wolfgang Bogner, Matthias Preusser, Georg Widhalm, Mathias Nittka, Gregor Koerzdoerfer, Pavol Szomolanyi, Gilbert Hangel,[...]. Cancers (Basel) 2022
0

Predictive accuracy of T2-FLAIR mismatch sign for the IDH-mutant, 1p/19q noncodeleted low-grade glioma: An updated systematic review and meta-analysis.
Yoon Ah Do, Se Jin Cho, Byung Se Choi, Sung Hyun Baik, Yun Jung Bae, Leonard Sunwoo, Cheolkyu Jung, Jae Hyoung Kim. Neurooncol Adv 2022
0

Innovating Strategies and Tailored Approaches in Neuro-Oncology.
Alberto Picca, David Guyon, Orazio Santo Santonocito, Capucine Baldini, Ahmed Idbaih, Alexandre Carpentier, Antonio Giuseppe Naccarato, Mario Caccese, Giuseppe Lombardi, Anna Luisa Di Stefano. Cancers (Basel) 2022
0

Noninvasive differentiation of molecular subtypes of adult nonenhancing glioma using MRI perfusion and diffusion parameters.
Ilanah J Pruis, Stephan R Koene, Sebastian R van der Voort, Fatih Incekara, Arnaud J P E Vincent, Martin J van den Bent, Geert J Lycklama À Nijeholt, Rishi D S Nandoe Tewarie, Sophie E M Veldhuijzen van Zanten, Marion Smits. Neurooncol Adv 2022
0

Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas.
Martin C Tom, Michael T Milano, Samuel T Chao, Scott G Soltys, Jonathan P S Knisely, Arjun Sahgal, Seema Nagpal, Simon S Lo, Siavash Jabbari, Tony J C Wang,[...]. Radiother Oncol 2022
0

Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics.
Saivenkat Vagvala, Jeffrey P Guenette, Camilo Jaimes, Raymond Y Huang. Cancer Imaging 2022
2

Comprehensive analysis of epigenetics regulation, prognostic and the correlation with immune infiltrates of GPX7 in adult gliomas.
Wallax Augusto Silva Ferreira, Glauco Akelinghton Freire Vitiello, Tiago da Silva Medina, Edivaldo Herculano Correa de Oliveira. Sci Rep 2022
1

Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States.
J Bryan Iorgulescu, Chuxuan Sun, Corey Neff, Gino Cioffi, Catherine Gutierrez, Carol Kruchko, Jennifer Ruhl, Kristin Waite, Serban Negoita, Jim Hofferkamp,[...]. Neuro Oncol 2022
1

Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation.
Nayan Lamba, Malia McAvoy, Vasileios K Kavouridis, Timothy R Smith, Mehdi Touat, David A Reardon, J Bryan Iorgulescu. Neurooncol Pract 2022
1

Lung toxicity of lomustine in the treatment of progressive gliomas.
Corinna Seliger, Christina Nürnberg, Wolfgang Wick, Antje Wick. Neurooncol Adv 2022
0

Revisiting the definition of glioma recurrence based on a phylogenetic investigation of primary and re-emerging tumor samples: a case report.
Toru Umehara, Hideyuki Arita, Fuyuki Miya, Takamune Achiha, Tomoko Shofuda, Ema Yoshioka, Daisuke Kanematsu, Tomoyoshi Nakagawa, Manabu Kinoshita, Naoki Kagawa,[...]. Brain Tumor Pathol 2022
0

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
A Wick, A Sander, M Koch, M Bendszus, S Combs, T Haut, A Dormann, S Walter, M Pertz, J Merkle-Lock,[...]. BMC Cancer 2022
0

Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours.
Craig Horbinski, Tamar Berger, Roger J Packer, Patrick Y Wen. Nat Rev Neurol 2022
0

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.
Andrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, Alba A Brandes, J Gregory Cairncross, Johan M Kros, Lynn S Ashby, Martin J B Taphoorn, Luis Souhami, Winand N M Dinjens,[...]. J Clin Oncol 2022
0

Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment.
Alireza Mafi, Atefe Rahmati, Zahra Babaei Aghdam, Raziyeh Salami, Marziyeh Salami, Omid Vakili, Esmat Aghadavod. Cell Mol Biol Lett 2022
0

MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.
David A Joyner, John Garrett, Prem P Batchala, Bharath Rama, Joshua R Ravicz, James T Patrie, Maria-B Lopes, Camilo E Fadul, David Schiff, Rajan Jain,[...]. Neuroradiology 2022
0

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Nimish A Mohile, Hans Messersmith, Na Tosha Gatson, Andreas F Hottinger, Andrew Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson,[...]. J Clin Oncol 2022
7

Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
Jasmin Jo, Martin J van den Bent, Burt Nabors, Patrick Y Wen, David Schiff. Neuro Oncol 2022
0

nTMS-derived DTI-based motor fiber tracking in radiotherapy treatment planning of high-grade gliomas for avoidance of motor structures.
Christian D Diehl, Enrike Rosenkranz, Martin Mißlbeck, Maximilian Schwendner, Nico Sollmann, Sebastian Ille, Bernhard Meyer, Stephanie E Combs, Denise Bernhardt, Sandro M Krieg. Radiother Oncol 2022
0

A Qualitative Signature to Identify TERT Promoter Mutant High-Risk Tumors in Low-Grade Gliomas.
Weicheng Zheng, Ruolan Zhang, Ziru Huang, Jianpeng Li, Haonan Wu, Yuwei Zhou, Jinwei Zhu, Xianlong Wang. Front Mol Biosci 2022
0

Validation Study for Non-Invasive Prediction of IDH Mutation Status in Patients with Glioma Using In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning.
Elisabeth Bumes, Claudia Fellner, Franz A Fellner, Karin Fleischanderl, Martina Häckl, Stefan Lenz, Ralf Linker, Tim Mirus, Peter J Oefner, Christian Paar,[...]. Cancers (Basel) 2022
0

Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.
Lia M Halasz, Albert Attia, Lisa Bradfield, Daniel J Brat, John P Kirkpatrick, Nadia N Laack, Nafisha Lalani, Emily S Lebow, Arthur K Liu, Heather M Niemeier,[...]. Pract Radiat Oncol 2022
0

Current and Future Frontiers of Molecularly Defined Oligodendrogliomas.
Jordina Rincon-Torroella, Maureen Rakovec, Josh Materi, Divyaansh Raj, Tito Vivas-Buitrago, Abel Ferres, William Reyes Serpa, Kristin J Redmond, Matthias Holdhoff, Chetan Bettegowda,[...]. Front Oncol 2022
0